Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Broadcom
AVGO
|
$67.3M |
| 2 |
Veralto
VLTO
|
$60.2M |
| 3 |
Newmont
NEM
|
$43.4M |
| 4 |
Celsius Holdings
CELH
|
$19.6M |
| 5 |
Vertiv
VRT
|
$19.4M |
Top Sells
| 1 |
Apple
AAPL
|
$328M |
| 2 |
Microsoft
MSFT
|
$244M |
| 3 |
ATVI
Activision Blizzard Inc.
ATVI
|
$237M |
| 4 |
VMW
VMware, Inc
VMW
|
$130M |
| 5 |
NVIDIA
NVDA
|
$109M |
Sector Composition
| 1 | Technology | 30.91% |
| 2 | Healthcare | 12.91% |
| 3 | Consumer Discretionary | 12.16% |
| 4 | Industrials | 9.37% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2576
LoveSac
LOVE
$278M
| – | – | -31,400 | Closed | -$625K |
|
2577
LivePerson
LPSN
$90.1M
| – | – | -156,200 | Closed | -$608K |
|
2578
Luxfer Holdings
LXFR
$359M
| – | – | -58,800 | Closed | -$767K |
|
2579
Lexicon Pharmaceuticals
LXRX
$400M
| – | – | -242,300 | Closed | -$264K |
|
2580
MBIA
MBI
$402M
| – | – | -107,700 | Closed | -$777K |
|
2581
Seres Therapeutics
MCRB
$166M
| – | – | -225,000 | Closed | -$536K |
|
2582
MINISO
MNSO
$7.59B
| – | – | -206,334 | Closed | -$5.34M |
|
2583
Mersana Therapeutics
MRSN
$36.5M
| – | – | -178,096 | Closed | -$226K |
|
2584
Nurix Therapeutics
NRIX
$714M
| – | – | -84,800 | Closed | -$667K |
|
|
NUTX
2585
Nutex Health
NUTX
$465M
| – | – | -780,978 | Closed | -$158K |
|
2586
Nuvation Bio
NUVB
$1.02B
| – | – | -258,100 | Closed | -$346K |
|
2587
Outset Medical
OM
$247M
| – | – | -102,800 | Closed | -$1.12M |
|
|
ONL
2588
Orion Office REIT
ONL
$167M
| – | – | -117,100 | Closed | -$610K |
|
2589
ON24
ONTF
$242M
| – | – | -68,700 | Closed | -$435K |
|
|
OPI
2590
Office Properties Income Trust
OPI
$15.8M
| – | – | -106,733 | Closed | -$438K |
|
2591
Origin Materials
ORGN
$80.2M
| – | – | -252,300 | Closed | -$323K |
|
2592
Organogenesis Holdings
ORGO
$653M
| – | – | -158,700 | Closed | -$505K |
|
2593
PetMed Express
PETS
$63.4M
| – | – | -45,900 | Closed | -$470K |
|
2594
ProKidney
PROK
$319M
| – | – | -66,401 | Closed | -$304K |
|
2595
uniQure
QURE
$896M
| – | – | -99,400 | Closed | -$667K |
|
2596
RE/MAX Holdings
RMAX
$189M
| – | – | -39,300 | Closed | -$509K |
|
2597
Rimini Street
RMNI
$401M
| – | – | -127,000 | Closed | -$279K |
|
2598
Repare Therapeutics
RPTX
$71.7M
| – | – | -40,700 | Closed | -$492K |
|
2599
Rackspace Technology
RXT
$302M
| – | – | -113,900 | Closed | -$268K |
|
2600
Sight Sciences
SGHT
$213M
| – | – | -69,314 | Closed | -$234K |
|